To further confirm the efficacy of BCR-ABL1 and PI3K/Akt/mTOR inhibitors, the expression of Ser473 p-Akt, Ser235/236 p-S6 and of Tyr207 p-CrkL, a downstream substrate of NUP214-ABL1 kinase [11], were evaluated in ALL-SIL, PEER and BE-13 cells. The gene discussed is CRKL; the disease is acute lymphoblastic leukemia.